Investigational drug · Phase 2
ABO-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Hyperoxaluria Type 1 (PH1).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ABO-101"
First trial start
2025
Jun 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABO-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Hyperoxaluria Type 1 (PH1)
Largest trials
Live from ClinicalTrials.gov: studies naming "ABO-101" as an intervention, largest first.
Arbor BiotechnologiesIndustry
NCT06839235 · 23 participants (planned) · Start Jun 16, 2025 · Primary completion Mar 2029
Drug: ABO-101 · For: Primary Hyperoxaluria Type 1 (PH1)
Sites: Rochester, Minnesota; Saint Paul, Minnesota; Lyon, France · 7 sites in all
Abeona Therapeutics, IncIndustry
NCT04655911 · 1 participants · Start Oct 28, 2020 · Primary completion Apr 7, 2022
Drug: ABO-101 · For: Mucopolysaccharidosis III-B
Sites: Columbus, Ohio; Paris, France; Hamburg, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.